The latest update is out from Keros Therapeutics ( (KROS) ).
On February 28, 2025, Keros Therapeutics announced that its Chair and CEO, Jasbir Seehra, will participate in fireside chat presentations at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025, and the Leerink Partners Global Healthcare Conference on March 10, 2025. These events are significant as they provide Keros with a platform to discuss its innovative therapeutic developments and engage with stakeholders, potentially impacting its industry positioning and investor relations.
More about Keros Therapeutics
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. The company is a leader in understanding the role of TGF-ß proteins, which regulate growth, repair, and maintenance of various tissues. Keros is developing protein therapeutics with potential disease-modifying benefits, including cibotercept for pulmonary arterial hypertension, KER-065 for neuromuscular diseases, and elritercept for cytopenias in myelodysplastic syndrome and myelofibrosis.
YTD Price Performance: -30.84%
Average Trading Volume: 1,673,669
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $446.6M
See more insights into KROS stock on TipRanks’ Stock Analysis page.